Advanced search
291
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Evaluating Twitter as a complementary data source for pharmacovigilance

ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 763-774
Received 19 Apr 2018
Accepted 09 Jul 2018
Accepted author version posted online: 10 Jul 2018
Published online: 26 Jul 2018
 

ABSTRACT

Background: Social media are currently considered as a potential complementary source of knowledge for drug safety surveillance. Our primary objective was to estimate the frequency of adverse drug reactions (ADRs) experienced by Twitter users. Our secondary objective was to determine whether tweets constitute a valuable and informative source of data for pharmacovigilance purposes, despite limitations on character number per tweet.

Research design and methods: We selected a list of 33 drugs subject to careful monitoring due to safety concern in France and Europe, and extracted tweets using the streaming API from 30 September 2014 to 5 April 2015. Two pharmacovigilance centers classified these tweets manually as potential ADR case reports.

Results: Among 10,534 tweets, 848 (8.05%) implied or mentioned an ADR without meeting the four FDA criteria required for reporting an ADR, and 289 (2.74%) tweets were classified as ‘case reports.’ Among them 20 (7.27%) tweets mentioned an unexpected ADR and 33 (11.42%) tweets mentioned a serious ADR.

Conclusions: With the use of dedicated tools, Twitter could become a complementary source of information for pharmacovigilance, despite a major limitation regarding causality assessment of ADRs in individual tweets, which may improve with the new limitation to 280 characters per tweet.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplementary data for this article can be accessed here.

Additional information

Funding

This work was funded by the AAP-2013-052 grant fromAgence nationale de sécurité du médicament et des produits de santé (ANSM), the French agency for drug safety, through the Vigi4MED research project, and Convention n°2016S076 through the PHARES project. The views expressed in this article are those of the authors and do not necessarily represent the views of the ANSM.

Notes on contributors

Jérémy Lardon

JL, FB, and CB wrote the protocol and the first draft of the article. CB designed and conducted the study, and wrote the final article. ALL, MNB, and MCJ provided significant advice on the design of the study. JS implemented the extraction and storage of tweets, and JL implemented the web based interface used for the evaluation study. FB, RA, HA, MNB, and ALL reviewed the tweets content and interpreted the data. All authors have made substantial contributions and approved the final manuscript, and agreed to be accountable for all aspects of the work.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
EUR 80.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
EUR 430.00 Add to cart

* Local tax will be added as applicable
 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.